{"transactions":[{"id":4628670,"issuer":{"id":9937,"kind":"organization","name":"Vertical Data Inc.","symbol":"VDTA"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO and Secretary"}}],"security":"Common Stock","published_at":"2026-10-02T23:12:09.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":891,"price":5.6065,"value":4995.3915,"ownership":{"direct":false,"nature":"By Lincoln Hall Advisors LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares issued under the Issuer's 2024 Stock Incentive Plan pursuant to Section 2.b of the Consulting Agreement in satisfaction of the $5,000 monthly equity fee for September 2026, received in shares in lieu of cash. The number of shares equals $5,000 divided by the volume-weighted average price of the Issuer's common stock on the OTCQB Marketplace for all trading days in September 2026 ($5.6065), rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Lincoln Hall Advisors LLC, a Wyoming limited liability company of which the Reporting Person is the sole member, through which the Reporting Person provides services to the Issuer."}],"balance_after":2248,"source":{"system":"sec-edgar","filing":"0001705978-26-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2033264/000170597826000004/primary_doc.xml","form_type":"4"}},{"id":4628669,"issuer":{"id":9937,"kind":"organization","name":"Vertical Data Inc.","symbol":"VDTA"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO and Secretary"}}],"security":"Common Stock","published_at":"2026-10-02T23:12:09.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":1357,"price":3.682,"value":4996.474,"ownership":{"direct":false,"nature":"By Lincoln Hall Advisors LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued under the Issuer's 2024 Stock Incentive Plan pursuant to Section 2.b of the Consulting Agreement between the Issuer and Lincoln Hall Advisors LLC, effective August 1, 2026, in satisfaction of the $5,000 monthly equity fee for August 2026, received in shares in lieu of cash. The number of shares equals $5,000 divided by the volume-weighted average price of the Issuer's common stock on the OTCQB Marketplace for all trading days in August 2026 ($3.6820), rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Lincoln Hall Advisors LLC, a Wyoming limited liability company of which the Reporting Person is the sole member, through which the Reporting Person provides services to the Issuer."}],"balance_after":1357,"source":{"system":"sec-edgar","filing":"0001705978-26-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033264/000170597826000004/primary_doc.xml","form_type":"4"}},{"id":993863,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase common stock","published_at":"2025-11-19T22:00:02.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":4881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the \"Grant Date\"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":4881,"derivative":{"exercise_price":30,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":4881},"source":{"system":"sec-edgar","filing":"0001683168-25-008562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316825008562/ownership.xml","form_type":"4"}},{"id":1543820,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-11T01:51:35.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units set forth in the table vest in eight equal quarterly installments over two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units set forth in the table vest in eight equal quarterly installments over two years."}],"balance_after":241.572,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001683168-24-002286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824002286/ownership.xml","form_type":"4"}},{"id":1543819,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase common stock","published_at":"2024-04-11T01:51:35.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in the table vest in 36 equal monthly installments over three years."}],"balance_after":201.572,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001683168-24-002286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824002286/ownership.xml","form_type":"4"}},{"id":1656809,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series B Warrant to purchase common stock","published_at":"2024-02-06T15:27:39.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":161572,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001683168-24-000706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824000706/ownership.xml","form_type":"4"}},{"id":1656808,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Warrant to purchase common stock","published_at":"2024-02-06T15:27:39.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":94906,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001683168-24-000706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824000706/ownership.xml","form_type":"4"}},{"id":1656807,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-02-06T15:27:39.000Z","date":"2024-02-01","kind":"purchase","planned":false,"acquired":true,"shares":66666,"price":0.3,"value":19999.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":103438,"source":{"system":"sec-edgar","filing":"0001683168-24-000706","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824000706/ownership.xml","form_type":"4"}},{"id":1798721,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-23T12:00:04.000Z","date":"2023-08-22","kind":"purchase","planned":false,"acquired":true,"shares":27000,"price":1.2658,"value":34176.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.2196 to $1.2999. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":36772,"source":{"system":"sec-edgar","filing":"0001683168-23-006001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823006001/ownership.xml","form_type":"4"}},{"id":1910198,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-01T22:59:47.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":false,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."}],"balance_after":28248,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001683168-23-002829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002829/ownership.xml","form_type":"4"}},{"id":1910197,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-01T22:59:47.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":9772,"source":{"system":"sec-edgar","filing":"0001683168-23-002829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002829/ownership.xml","form_type":"4"}},{"id":1918130,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-18T12:00:05.000Z","date":"2023-04-17","kind":"purchase","planned":false,"acquired":true,"shares":3100,"price":3.2,"value":9920.0,"ownership":{"direct":true},"balance_after":9251,"source":{"system":"sec-edgar","filing":"0001683168-23-002495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002495/ownership.xml","form_type":"4"}},{"id":1934020,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-31T23:28:10.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":6067,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events)."}],"balance_after":28768,"derivative":{"underlying":"Common stock","underlying_shares":6067},"source":{"system":"sec-edgar","filing":"0001683168-23-002095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002095/ownership.xml","form_type":"4"}},{"id":2022781,"issuer":{"id":95571,"kind":"organization","name":"EBET, Inc.","symbol":"EBET"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-10T22:34:01.000Z","date":"2023-02-09","kind":"exercise","acquired":false,"shares":6300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Issued upon conversion of restricted stock units, each of which represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's service as a director to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table were issued February 9, 2022 and vested on February 9, 2023, subject to the grantee's continued service to the Issuer on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table were issued February 9, 2022 and vested on February 9, 2023, subject to the grantee's continued service to the Issuer on such vesting date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001683168-23-000760","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823000760/ownership.xml","form_type":"4"}},{"id":2022780,"issuer":{"id":95571,"kind":"organization","name":"EBET, Inc.","symbol":"EBET"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-10T22:34:01.000Z","date":"2023-02-09","kind":"exercise","acquired":true,"shares":6300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Issued upon conversion of restricted stock units, each of which represents a contingent right to receive one share of Issuer common stock."}],"balance_after":6300,"source":{"system":"sec-edgar","filing":"0001683168-23-000760","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823000760/ownership.xml","form_type":"4"}},{"id":2287936,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-04-29T21:12:32.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."}],"balance_after":681000,"derivative":{"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001683168-22-003054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316822003054/ownership.xml","form_type":"4"}},{"id":2335570,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-14T13:40:12.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":33000,"price":0.31,"value":10230.0,"ownership":{"direct":true},"balance_after":184500,"source":{"system":"sec-edgar","filing":"0001683168-22-001631","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316822001631/ownership.xml","form_type":"4"}},{"id":2401802,"issuer":{"id":95571,"kind":"organization","name":"EBET, Inc.","symbol":"EBET"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-11T21:36:48.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":6300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's service as a director to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest on the earlier of one-year from the date of issuance or the date of the Issuer's next annual meeting of shareholders, subject to the grantee's continued service to the Issuer on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest on the earlier of one-year from the date of issuance or the date of the Issuer's next annual meeting of shareholders, subject to the grantee's continued service to the Issuer on such vesting date."}],"balance_after":81300,"derivative":{"underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001683168-22-000872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316822000872/ownership.xml","form_type":"4"}},{"id":2482324,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-07T13:30:08.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":5000,"price":0.9403,"value":4701.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.9400 to $0.947299. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":151500,"source":{"system":"sec-edgar","filing":"0001683168-21-006141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316821006141/ownership.xml","form_type":"4"}},{"id":2500904,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-22T13:47:56.000Z","date":"2021-11-19","kind":"purchase","acquired":true,"shares":4500,"price":1.1537,"value":5191.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.14 to $1.155. The price reported above reflects the weighted average purchase\nprice. The reporting person hereby undertakes to provide upon upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of\nshares and prices at which the transaction was effected."}],"balance_after":146500,"source":{"system":"sec-edgar","filing":"0001683168-21-005869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316821005869/ownership.xml","form_type":"4"}},{"id":2872022,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase common stock (right to buy)","published_at":"2021-02-09T22:00:38.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":131000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date."}],"balance_after":431000,"derivative":{"exercise_price":3.36,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":131000},"source":{"system":"sec-edgar","filing":"0001683168-21-000448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316821000448/ownership.xml","form_type":"4"}},{"id":3047741,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-25T23:11:45.000Z","date":"2020-08-24","kind":"purchase","acquired":true,"shares":142000,"price":2.04,"value":289680.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.84 to $2.30. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142000,"source":{"system":"sec-edgar","filing":"0001683168-20-002862","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316820002862/ownership.xml","form_type":"4"}},{"id":3373025,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase common stock (right to buy)","published_at":"2019-11-13T22:12:29.000Z","date":"2019-11-13","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date."}],"balance_after":300000,"derivative":{"exercise_price":4,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001683168-19-003571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316819003571/ownership.xml","form_type":"4"}},{"id":4213698,"issuer":{"id":6163,"kind":"organization","name":"InfuSystem Holdings, Inc","symbol":"INFU"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Stock Option (right to buy)","published_at":"2017-09-08T23:06:54.000Z","date":"2017-09-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, representing the right to purchase a total of 25,000 shares of InfuSystem Holdings, Inc. common stock, vests annually over three years beginning September 7, 2018."}],"balance_after":25000,"derivative":{"exercise_price":1.98,"expiration_date":"2022-09-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001014108-17-000151","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000101410817000151/primary_doc.xml","form_type":"4"}},{"id":4232622,"issuer":{"id":6163,"kind":"organization","name":"InfuSystem Holdings, Inc","symbol":"INFU"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO (interim)"}}],"security":"Common Stock","published_at":"2017-08-16T22:31:28.000Z","date":"2017-08-14","kind":"purchase","acquired":true,"shares":7900,"price":1.9,"value":15010.0,"ownership":{"direct":true},"balance_after":28840,"source":{"system":"sec-edgar","filing":"0001014108-17-000135","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000101410817000135/primary_doc.xml","form_type":"4"}},{"id":4331805,"issuer":{"id":6163,"kind":"organization","name":"InfuSystem Holdings, Inc","symbol":"INFU"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO (interim)"}}],"security":"Stock Option (right to buy)","published_at":"2017-05-05T21:16:43.000Z","date":"2017-03-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, representing the right to purchase a total of 20,000 shares of InfuSystem Holdings, Inc. common stock, vests in 36-monthly installments beginning April 16, 2017."}],"balance_after":20000,"derivative":{"exercise_price":2.15,"expiration_date":"2027-03-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001014108-17-000099","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000101410817000099/primary_doc.xml","form_type":"4"}},{"id":4331804,"issuer":{"id":6163,"kind":"organization","name":"InfuSystem Holdings, Inc","symbol":"INFU"},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO (interim)"}}],"security":"Stock Option (right to buy)","published_at":"2017-05-05T21:11:38.000Z","date":"2016-08-18","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, representing the right to purchase a total of 60,000 shares of InfuSystem Holdings, Inc. common stock, vests in 36-monthly installments beginning September 18, 2016."}],"balance_after":60000,"derivative":{"exercise_price":2.76,"expiration_date":"2026-08-18","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001014108-17-000098","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000101410817000098/primary_doc.xml","form_type":"4"}}]}